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Mutations in NDUFB11, Encoding a Complex I
Component of the Mitochondrial Respiratory Chain,
Cause Microphthalmia with Linear Skin Defects Syndrome
Vanessa A. van Rahden,1,8 Erika Fernandez-Vizarra,2,8 Malik Alawi,3,4,5 Kristina Brand,1
Florence Fellmann,6 Denise Horn,7 Massimo Zeviani,2 and Kerstin Kutsche1,*
Microphthalmia with linear skin defects (MLS) syndrome is an X-linked male-lethal disorder also known as MIDAS (microphthalmia,
dermal aplasia, and sclerocornea). Additional clinical features include neurological and cardiac abnormalities. MLS syndrome is genet-
ically heterogeneous given that heterozygous mutations in HCCS or COX7B have been identified in MLS-affected females. Both genes
encode proteins involved in the structure and function of complexes III and IV, which form the terminal segment of the mitochondrial
respiratory chain (MRC). However, not all individuals with MLS syndrome carry a mutation in either HCCS or COX7B. The majority of
MLS-affected females have severe skewing of X chromosome inactivation, suggesting that mutations inHCCS, COX7B, and other as-yet-
unidentified X-linked gene(s) cause selective loss of cells in which the mutated X chromosome is active. By applying whole-exome
sequencing and filtering for X-chromosomal variants, we identified a de novo nonsense mutation in NDUFB11 (Xp11.23) in one female
individual and a heterozygous 1-bp deletion in a second individual, her asymptomatic mother, and an affected aborted fetus of the sub-
ject’s mother. NDUFB11 encodes one of 30 poorly characterized supernumerary subunits of NADH:ubiquinone oxidoreductase, known
as complex I (cI), the first and largest enzyme of theMRC. By shRNA-mediatedNDUFB11 knockdown in HeLa cells, we demonstrate that
NDUFB11 is essential for cI assembly and activity as well as cell growth and survival. These results demonstrate that X-linked genetic
defects leading to the complete inactivation of complex I, III, or IV underlie MLS syndrome. Our data reveal an unexpected role of cI
dysfunction in a developmental phenotype, further underscoring the existence of a group ofmitochondrial diseases associatedwith neu-
rocutaneous manifestations.The microphthalmia with linear skin defects (MLS)
syndrome (MIM 309801) is an X-linked neurocutaneous
disorder manifesting exclusively in females, suggesting
embryonic lethality in hemizygousmales. Affected females
typically show uni- or bilateral microphthalmia and/or
anophthalmia and linear skin lesions, which are usually
restricted to the face and neck and consist of aplastic skin
that evolves into healed hyperpigmented areas. Facultative
features include a great variety of ocular anomalies, such as
microcornea, coloboma, anterior-chamber defects, optic-
nerve hypoplasia, retinal abnormalities, congenital glau-
coma with peripheral anterior synechia, and cataracts.
Other clinical characteristics, such as developmental delay,
abnormalities of the central nervous system (CNS), short
stature, and cardiac defects have also been observed (see
GeneReviews in Web Resources).1–3 Although most
affected females show the classical phenotype, a few re-
ported individuals have displayed eye abnormalities in
an absence of skin defects,2–7 and in other individuals,
skin defects in an absence of ocular anomalies have been
described.8–10
MLS syndrome is a genetically heterogeneous disorder
given that mutations in two different X-chromosomal
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tion, detectable by light microscopy. The deletions include
HCCS in Xp22.2 (MIM 300056; RefSeq accession number
NM_005333.4) (see GeneReviews in Web Resources).
HCCS encodes the mitochondrial holocytochrome c-type
synthase.12,13 After this initial observation, heterozygous
submicroscopic interstitial deletions and intragenic
mutations of HCCS were detected in females with the
classical MLS phenotype, confirming a pathogenic role
for HCCS disruption in MLS.1–3,7,14,15 More recently, het-
erozygous mutations in COX7B (MIM 300885; RefSeq
NM_001866.2), located in chromosome band Xq21.1,
have been found in girls who had linear skin defects
as the predominant feature but who had no HCCS
mutation or microphthalmia.11 COX7B encodes a struc-
tural subunit of cytochrome c oxidase, also known as
mitochondrial complex IV (cIV).16,17 cIV is one of the
five enzymatic complexes (cI–cV) of the mitochondrial res-
piratory chain (MRC), which carries out oxidative phos-
phorylation (OXPHOS). Both HCCS and COX7B gene
products are indispensable for MRC biogenesis and func-
tion. HCCS catalyzes the incorporation of heme moieties
in both cytochrome c1, a structural component of cIII,
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Table 1. Clinical Features Reported in MLS-Affected Individuals with a Mutation of HCCS, COX7B, or NDUFB11
Clinical Features
HCCSa,b
Mutation
COX7Bc
Mutation
NDUFB11
Mutation
Occurence Occurence Subject 1 Subject 2
Mother of
Subject 2
Aborted Fetus of
Subject-2’s Mother
Microphthalmia 51/63 (81%) 0/4 – – – NA
Sclerocornea 29/63 (46%) 0/4 – – – NA
Other eye abnormalities 34/63 (54%) 1/4 þ þ – NA
Linear skin lesions 47/63 (75%) 4/4 þ þ – NA
Nail dystrophy 3/55 (5%) 4/4 – – – NA
Microcephaly, agenesis of
the corpus callosum, and
other CNS abnormalities
27/59 (46%) 3/4 –d þ – þ
Developmental delay and/or
intellectual disability
11/49 (22%) 2/4 NA hypotonia þ hypotonia – NA
Short stature 18/42 (43%) 2/4 NA þ – intrauterine growth
retardation
Cardiac abnormalities 22/60 (37%) 2/4 þ þ – þ
Diaphragmatic hernia 3/63 (5%) 1/4 – – – –
Genitourinary abnormalities 14/63 (22%) 1/4 – – – –
Other anomalies NA NA thyroid abnormalities (large
and multiple sites of oncocytic
metaplasia) after autopsy
seizures,
epilepsy
– –
Clinical features in this table correspond to those in Table 1 in Indrieri et al.11 For each feature listed in the table, the total number of individuals includes only
individuals in whom each clinical feature was analyzed and documented. Other anomalies are only given for individuals with anNDUFB11mutation. Abbreviations
are as follows: –, absent; þ, present; NA, not applicable.
aMutations in HCCS include intragenic alterations and chromosomal abnormalities that result in monosomy for Xp22.
bSee GeneReviews in Web Resources and Sharma et al.,25 Kono et al.,6 Zumwalt et al.,26 Vergult et al.,15 and van Rahden et al.2
cSee Indrieri et al.11
dBrain size and morphology were normal; an autopsy showed no corpus callosum agenesis.IV.12,13 Complementation studies in yeast revealed that
HCCS deficiency led to severe OXPHOS defects.18 Similarly,
depletion of COX7B impairs cIV assembly and activity,
leading to severe OXPHOS failure.11
Because the cIII–cIV MRC segment is impaired in indi-
viduals with MLS syndrome, this disorder is by definition
a mitochondrial disease. However, whereas typical mito-
chondrial diseases are usually characterized by postnatal
organ failure,19,20 MLS syndrome is a truly developmental
phenotype, in that it involves impaired development and
malformation of specific organs, such as the eyes, skin,
and CNS. Linear skin defects, which are present at birth,
are themajor clinical criteria ofMLS syndrome. The lesions
follow the lines of Blaschko, heal with age, and leave scars
in some cases (see GeneReviews in Web Resources). Down-
regulation of hccs or cox7b in medaka has been shown to
recapitulate the MLS phenotype; the morphant fishes
show microphthalmia and microcephaly, indicating
the important roles of cIII and cIV in vertebrate CNS
development.11,18
High inter- and intrafamilial phenotypic variabilities
have been reported in females with MLS syndrome.3,21–23
The spectrum of clinical features ranges widely, from a
neonatal lethal form ofMLS syndrome to no apparent clin-The Amical sign in carrier females.1–3,7,9,21,22,24 In Table 1 we
compare the clinical features described in females positive
for the HCCS or COX7B mutation. Somatic mosaicism for
the causative mutation and the degree of X chromosome
inactivation (XCI) skewing in different tissues have been
postulated as explanations for the great clinical variability
of MLS.2,3,24,27,28 Positive selection of OXPHOS-proficient
cells during development could result in extreme skewing
of the XCI ratio in females positive for theHCCS or COX7B
mutation.2,11 Indeed, monoallelic expression of the wild-
type X chromosome was shown in lymphoblastoid cells
of an MLS-affected female with the heterozygous HCCS
nonsense mutation c.589C>T (p.Arg197*).3 These results
suggest that, during embryonic development, cells with
an active wild-type X chromosome are likely to reproduce
faster and eventually outgrow cells expressing the COX7B-
or HCCS-mutation-bearing X chromosome and that this
faster growth leads to skewed XCI and high clinical vari-
ability.2,29 Thus, MLS syndrome is the result of extremely
severe MRC disruption combined with inactivation of
the X chromosome. Importantly, because cells expressing
the mutated X chromosome are filtered out during devel-
opment, no obvious biochemical defect of MRC activities
is detected in the cells of MLS-affected females (see below).erican Journal of Human Genetics 96, 640–650, April 2, 2015 641
Figure 1. Pictures of Two Subjects with MLS Syndrome and the NDUFB11 Mutation
(A) Pedigree of subject 1’s (S1’s) family and segregation analysis of the NDUFB11 mutation c.262C>T.
(B) At the age of 6 weeks, subject 1 had linear skin defects on her face and ears.
(C) Pedigree of subject 2’s (S2’s) family and segregation analysis of the 1-bp deletion c.402delG in NDUFB11. The mother of subject 2 is a
healthy carrier of the NDUFB11 mutation; she aborted a female fetus who had severe brain and heart anomalies and carried the same
mutation.
(D and E) Subject 2 (2 months of age) had linear skin defects on the nose, chin, neck, and left ear lobe. Abbreviations are as follows: Mut,
NDUFB11 mutation; wk, weeks; WT, wild-type.In DNA samples taken from 11MLS-affected females and
pooled from two different labs, sequencing and copy-num-
ber analysis failed to detect a mutation in either HCCS or
COX7B.11 In our own cohort of seven individuals, whole-
exome sequencing (WES) revealed heterozygous trun-
cating mutations in NDUFB11 (MIM 300403; RefSeq
NM_019056.6), located in chromosomal band Xp11.23,
in two unrelated female probands. Both had a highly
skewed XCI pattern in peripheral blood cells and typical
features of MLS syndrome, except for the absence of micro-
phthalmia and sclerocornea (Table 1). Subject 1 belongs to
a simplex family. Subject 2 was a 15-month-old girl whose
asymptomatic mother subsequently aborted a female fetus
with severe malformations; all three harbored the same
heterozygous mutation in NDUFB11. The five remaining
individuals in our cohort showed no mutation in
NDUFB11, and WES is underway. In all cases, genetic anal-
ysis was performed with informed consent, including con-
sent to use photographs in this report, and was approved
by the ethics committee of the Medical Chamber of
Hamburg (reference numbers PV3585 and PV3802).
Subject 1 was an infant girl born to healthy, non-consan-
guineous parents (Figure 1A and Table 1). Her birth weight
was 3,060 g (10th–25th centile), her length was 50 cm (50th
centile), and her occipito-frontal head circumference
(OFC) was 36.5 cm (90th centile). Linear skin defects that
disappeared in the first few months were noted on her
nose, chin, and neck (Figure 1B). Axial hypotonia was pre-
sent from birth. Failure to thrive was documented at
1 month of age. Ocular examination revealed lacrimal-
duct atresia but neither microphthalmia nor sclerocornea.
Blood lactate levels were consistently in the normal range.
She was admitted to the hospital at 6months of age for car-
diac arrest. She was repeatedly treated for ventricular fibril-
lation and tachycardia but died a few weeks after admis-
sion. An autopsy revealed histiocytoid cardiomyopathy
and thyroid abnormalities consisting of large and multiple642 The American Journal of Human Genetics 96, 640–650, April 2, 2sites of oncocytic metaplasia. Immunohistochemical stain-
ing showed that oncocytic cells were thyroid transcription
factor-1 (TTF-1) positive and cytokeratin 19 (CK19) nega-
tive. An anti-calcitonin antibody showed several sites of
C cell hyperplasia (more than 50 C cells in at least threemi-
croscope fields [1003 magnification]).
Subject 2 was a 15-month-old girl, the first child of
German, non-consanguineous, healthy parents (Figure 1C
and Table 1). During pregnancy, corpus-callosum agenesis
as well as dilated lateral ventricles were detected by ultra-
sound and confirmed by prenatal magnetic resonance im-
aging (MRI) of the brain. Measurements at birth (41st
week of gestation) were normal and included a weight of
3,570g (50th–75th centile), a lengthof 51 cm (25th–50th cen-
tile), and anOFC of 34.5 cm (25th–50th centile). After birth,
linear and atrophic hyperpigmented streaks onher face and
neck (Figures 1D and 1E) as well as on her left index finger
werenoticed.At 2monthsof age, seizures,which responded
well to anticonvulsants, occurred. At the same age, dilated
cardiomyopathy ensued, prompting a heart transplanta-
tionat 6monthsof age.At 15monthsof age, anophthalmo-
logic examination revealed myopia, nystagmus, and stra-
bismus, but neither microphthalmia nor sclerocornea.
Over time, severe psychomotor developmental delay
became evident; she was able to roll at 15 months of age
and to sit at 18 months. She started walking at 3 years of
age. At 7 years of age, shewas able to speak in simple senten-
ces and had sphincter control. At 15 months of age, her
height (73.5 cm, 2.1 SD), weight (7.5 kg, 2.7 SD), and
OFC (41 cm, 4.4 SD) were below the third centile. Severe
muscular hypotonia and delayed dentition were present.
A brainstem auditory evoked response demonstrated
normal hearing. Conventional cytogenetic analysis re-
vealed normal results. At 2.5 years of age, MRI of the brain
confirmed agenesis of corpus callosum and enlarged ventri-
cles. Blood lactatewasmeasured at the ages of 6months and
4.5 years and was in the normal range both times.015
In the next pregnancy of subject-2’s mother, an ultra-
sound examination of the female fetus at the 24th week
of gestation showed a thickened myocardium and pericar-
dial effusion, corpus-callosum dysgenesis, a small cere-
bellum, and a connection between a lateral ventricle and
the cavum septum pellucidum, as well as intrauterine
growth retardation (Table 1). The pregnancy was termi-
nated (Figure 1C).
High-resolution molecular karyotyping with the Agilent
180K Oligo Array (Agilent Technologies) revealed no dis-
ease-associated copy-number variant (CNV) in subject 1.
Array comparative genomic hybridization (CGH) with
the Agilent Human Genome Microarray Kit 244K was per-
formed on the DNA sample obtained from the aborted
fetus of subject-2’s mother and detected a heterozygous
deletion of at least 70 kb at 2p16.3, containing part of
NRXN1 (data not shown). Quantitative real-time PCR
confirmed the microdeletion in the fetal DNA and identi-
fied the same CNV in both subject 2 and her mother but
excluded this CNV in the father (data not shown). Hetero-
zygous intragenic mutations and deletions of NRXN1 are
enriched in cohorts of persons with autism spectrum disor-
der and neurodevelopmental disorders when these indi-
viduals are compared to control individuals. Incomplete
penetrance has been described; some healthy parents carry
the same deletion as the affected child.30–32 Therefore, we
cannot exclude the possibility that the NRXN1 deletion
might have contributed to the neurological phenotype in
subject 2 (for instance, by worsening developmental
delay). However, this copy-number loss is highly unlikely
to be causative for the multiple congenital anomalies
observed in this girl.
We next determined the XCI pattern by quantitative ex-
amination of the methylation status at the AR (androgen
receptor) locus.2,33 Leukocyte-derived DNA of subject 1
showed a highly skewed XCI pattern with a 10:90 ratio,
whereas her healthy mother had a less skewed XCI ratio
(20:80). In peripheral blood cells of subject 2 and her
healthy mother, we detected complete skewing (100:0).
Likewise, an XCI ratio of 99:1 was found in DNA from
the aborted fetus of subject-2’s mother (data not shown).
Given that complete or highly skewed XCI was observed
in COX7B- or HCCS-mutation-positive females,2,3,7,11
these findings strongly suggest that subjects 1 and 2
harbored mutations affecting a currently unidentified
X-linked gene.
We then performed WES of peripheral blood DNA from
subject 1 and her parents as well as from subject 2 and her
mother by using the Illumina TruSeq Exome Enrichment
Kit and an Illumina HiSeq 2500 sequencer. We aligned
the sequence to the human genome reference sequence
(UCSC Genome Browser hg19) by using the Burrows-
Wheeler Aligner (BWA).34 We used SAMtools to remove
potential PCR duplicates from the alignments and the
Genome Analysis Toolkit (GATK) for calling single-nucleo-
tide variants (SNVs) and indels.35 In addition, SAMtools
was used for calling a second set of variants from the dedu-The Amplicated alignments.36 Variant effects were predicted with
SnpEff.37 For each individual, the two sets of variant calls
were used for variant filtration and prioritization. In both
families, we identified common variants (minor-allele fre-
quency R1%) by filtering exome data against data in
dbSNP version 137, the NHLBI Exome Variant Server,
and the ExAC Browser. A detailed description of WES can
be found elsewhere.38 Exome read-depth metrics are sum-
marized in Table S1.
Highly skewed XCI in subject 1 and slight skewing in her
mother suggested the presence of an X-chromosomal de
novo mutation in subject 1. In contrast, severely skewed
XCI in subject 2, her asymptomatic mother, and the
severely affected fetus led us to hypothesize that the
mother carried an X-chromosomal variant that was in-
herited by both of her children. Indeed, carrier females
with an HCCS mutation or terminal Xp deletion but with
no clinical features of MLS syndrome have been
described.2,3,24 By applying this filter strategy, we identi-
fied the heterozygous de novo variant c.262C>T in
NDUFB11 (Xp11.23) in subject 1. This variant is predicted
to lead to the introduction of a premature stop codon
(p.Arg88*) (Figure 2A and Table S2). Notably, the mutated
base thymine was present in 42 sequence reads and the
wild-type base cytosine in 84, suggesting that themutation
was present in mosaic state in subject-1’s lymphocytes
(data not shown). In subject 2 and her healthy mother,
three heterozygous X-chromosomal sequence variants
were identified: two missense variants, c.1496A>G
(p.Asn499Ser) in ARSH (MIM 300586; RefSeq
NM_001011719.1) and c.3498G>T (p.Lys1166Asn) in
DGKK (MIM 300837; RefSeq NM_001013742.3), and the
frameshift mutation c.402delG (p.Arg134Serfs*3) in
NDUFB11 (Figure 2B and Table S2). The variants in
NDUFB11 and ARSHwere absent in dbSNP, 1000 Genomes,
the NHLBI Exome Variant Server, and the ExAC Browser,
whereas the rare DGKK variant was annotated (Table S2).
Validation of all variants was achieved with standard
bidirectional Sanger methods (primer sequences are
available on request). Further evidence of mosaicism of
the NDUFB11 c.262C>T mutation came from Sanger
sequencing of DNA isolated from leukocytes and fibroblast
cells of subject 1; the two different sequence profiles
showed a low signal for the mutant variant (thymine)
superimposed on the wild-type sequence (cytosine)
(Figure 2A). Sanger sequencing in the family of subject 2
excluded the three X-chromosomal variants in the sub-
ject’s father (paternity confirmed; Table S2). The two
missense variants in ARSH and DGKK are predicted by
SIFT, SNAP, PolyPhen-2, and/or MutationTaster to not
interfere with protein function (Table S2). Together, the
identification of two unrelated individuals who had typical
features of MLS syndrome and each carried a heterozygous
loss-of-function mutation in NDUFB11 indicated pathoge-
nicity of the sequence changes c.262C>T (p.Arg88*) and
c.402delG (p.Arg134Serfs*3). This conclusion is further
supported by the presence of the 1-bp deletion c.402delGerican Journal of Human Genetics 96, 640–650, April 2, 2015 643
Figure 2. NDUFB11 Mutations in Sub-
jects 1 and 2
(A) Sequence electropherograms of part of
NDUFB11 exon 2 from subject 1’s genomic
DNA (gDNA) isolated from blood (upper
panel) and gDNA and mRNA (cDNA) of
dermal skin fibroblasts (middle and lower
panels, respectively). Nucleotide triplets
and encoded amino acids (three-letter
code) are indicated above the electrophero-
grams. The red arrow points to the double
peak in the two upper electropherograms;
the lower peak of the mutant base (T) is
superimposed on the higher peak of the
wild-type base (C). Subject 1 carries the
mosaic NDUFB11mutation c.[ ¼ /262C>T]
(p.[ ¼ /Arg88*]).
(B) Sequence electropherograms of part of
NDUFB11 exon 3 from gDNA of subject 2
(upper panel), the aborted fetus (second
from the top panel), and their healthy
mother (second from the bottom panel).
Nucleotide triplets and encoded amino
acids of the wild-type and mutated allele
are indicated above the electrophero-
grams. The red arrow points to the first
double peak in the electropherograms
and indicates the start of the frameshift.
The three individuals are heterozygous for the NDUFB11 mutation c.402delG (p.Arg134Serfs*3). The sequence electropherogram
from leukocyte-derived mRNA (cDNA) of subject 2 shows only wild-type NDUFB11 transcripts (bottom panel).in NDUFB11 in DNA isolated from the severely malformed
fetus of subject-2’s mother (Table 1 and Figures 1D and 2B).
The NDUFB11 gene product is the 17.3-kDa subunit 11 of
the NADH dehydrogenase (ubiquinone) 1 beta subcom-
plex and is part of the MRC cI. NDUFB11 comprises three
exons; exon 2 is alternatively spliced.39 The c.262C>T
transition is located in exon 2, upstream of the alterna-
tively used splice donor site (last 30 nucleotides), and the
c.402delG mutation is located in exon 3. The longer tran-
script encodes a 163 amino acid (aa) protein, while the
shorter one encodes a more abundant protein consisting
of 153 aa.39 Human NDUFB11, also called NP17.3
(neuronal protein 17.3), corresponds to the ESSS protein
subunit in the nomenclature of bovine heart cI.40,41 Com-
plex I, or NADH:ubiquinone oxidoreductase, is the largest
enzyme of the mitochondrial electron-transport chain and
has two critical functions: NADH oxidation and formation
of membrane potential via proton translocation. Bovine,
and presumably human, cI is composed of 45 subunits,
seven of which are encoded by the mitochondrial
DNA.42 Only 14 conserved core subunits are essential for
energy transduction.43 The function of the 30 supernu-
merary subunits, including NDUFB11, is still poorly under-
stood. They might participate in complex stabilization,
protection of the core subunits against oxidative stress, as-
sembly of the complex, and/or regulation of complex ac-
tivity.44,45 Together, the products of HCCS and COX7B,
the two other genes with a known association to MLS, as
well as the products of NDUFB11, are all involved in
OXPHOS system biogenesis,12,13,16,17,40,46 underscoring
the existence of a new group of mitochondrial diseases644 The American Journal of Human Genetics 96, 640–650, April 2, 2with neurodevelopmental and skin defects as the major
clinical features. To test the idea that the extremely skewed
XCI found in our MLS-affected subjects was due to strong
selection against OXPHOS-faulty cells expressing mutant
NDUFB11, we performed RT-PCR analysis followed by
Sanger sequencing of reverse-transcribed total RNA. As ex-
pected, we identified only wild-type NDUFB11 transcripts
in fibroblast cells of subject 1 (Figure 2A) as well as in leu-
kocytes of subject 2 and her mother (Figure 2B and data
not shown). In concordance with these data, cells from
an affected individual do not show a cI defect (Table S3)
because NDUFB11 is exclusively expressed by the normal
gene present on the wild-type X chromosome. Conse-
quently, fibroblasts from affected females are unsuitable
for use in investigations of the biochemical consequences
of defective NDUFB11. To overcome this problem, we
decided to silence NDUFB11 in HeLa cells by stably ex-
pressing each of five different shRNAs (shRNA-1 to
shRNA-5), all targeting the NDUFB11 mRNA. HeLa cells
transduced with the empty pLKO.1 vector were used as a
control. The degree of NDUFB11 silencing was evaluated
with immunoblot analysis of the corresponding protein.
The amount of NDUFB11 was decreased in all five
NDUFB11-depleted cell lines; the lowest amount was
achieved in the shRNA-1-expressing cells, where NDUFB11
was virtually undetectable, and shRNA-2-expressing cells,
which showed a residual protein amount of ~5% of the
amounts in controls (Figure 3A). Interestingly, the amount
of another cI membrane-arm subunit, NDUFB8, was as
decreased as NDUFB11 in the five NDUFB11-knockdown
cell lines (shRNA-1 to shRNA-5) (Figure 3A). The low015
Figure 3. Impaired Assembly and Activ-
ity of CI in NDUFB11-Depleted HeLa Cells
(A) HeLa cells were stably transfected with
one of five different MISSION shRNA1-5
clones (TRCN0000107101–105, Sigma-Al-
drich) targeting the NDUFB11 mRNA or
with the empty vector pLKO.1. Immuno-
blotting with an anti-NDUFB11 antibody
(Proteintech) allowed NDUFB11 depletion
to be monitored. The antibodies against
NDUFB8, NDUFS3, MTCO1 (cytochrome
c oxidase subunit 1; theoretical molecular
mass of 57 kDa, but migrating at an
apparent molecular mass of 37 kDa in
SDS-PAGE), and cytochrome b-c1 complex
subunit 2 (UQCRC2) were from Abcam
(formerly Mitosciences). An anti-b-actin
antibody (Sigma-Aldrich) was used as the
loading control.
(B) IGA of cI and cIV on 1D-BNGE47 in
the five NDUFB11-knockdown cell lines
(shRNA1-5) and the control (pLKO.1). 1D-
BNGEwas performed onmitoplasts solubi-
lized with 1% DDM (n-Dodecyl b-D-malto-
side).48 The intensity of the cI-specific
signals representing the active monomer
(CI) and the active cI associated with the
otherMRC complexes in the form of super-
complexes (SCs) was markedly reduced in
HeLa cells stably expressing NDUFB11
shRNA-1 or -2 (upper panel). In contrast,
cIV-IGAwas comparable in all the samples.
(C) Immunodetection of cI-assembly intermediates on 2D-BNGE immunoblot with antibodies against NDUFB11, NDUFA9 (Abcam), and
NDUFS3. The NDUFS3-containing assembly intermediates detected in both control (pLKO.1) and NDUFB11 shRNA-1-depleted cells are
marked by black arrowheads; the NDUFS3-containing subcomplexes of the cI peripheral arm accumulated only in the shRNA-1 cells are
marked by gray arrowheads. An anti-COX4 antibody (Abcam; theoretical molecular mass of 19.5 kDa but migrating at an apparent
molecular mass of 15 kDa in SDS-PAGE) was used as a loading control.amount of NDUFB8 in the knockdown cells was not due to
reduced mRNA levels, given that these were even slightly
higher than mRNA levels in control cells (Figure S1). This
result excludes an off-target effect of the shRNA silencing
NDUFB11, suggesting that the absence of the NDUFB11
subunit might destabilize the region where both NDUFB11
and NDUFB8 subunits are located in the cI membrane
arm.42 This is further supported by the observation that
NDUFS3, a cI subunit that takes part in the peripheral
arm of the complex, was detected in a normal amount in
shRNA-transduced cells (Figure 3A). Likewise, cIII and cIV
were not affected by NDUFB11 silencing, given that the
amount of both UQCRC2 (ubiquinol-cytochrome c reduc-
tase core protein II, part of cIII) and MTCO1 (mtDNA-en-
coded cytochrome c oxidase subunit 1, part of cIV) was
the same in all tested cell lines (Figure 3A). These results
suggest that NDUFB11 is necessary for the assembly of
the membrane arm of cI, and thus for the assembly of
the cI holocomplex as well.
We next assessed cI in-gel activity (cI-IGA) by performing
one-dimensional blue-native gel electrophoresis (1D-
BNGE) in mitochondrial extracts from the five NDUFB11-
knockdown cell lines and the pLKO.1 control cell line.
The specific cI-reactive band was markedly reduced in
HeLa cells expressing shRNA-1 and shRNA-2 and was
reduced but clearly visible in shRNA-3 cells, whereas theThe Amsignal detected in shRNA-4 and shRNA-5 cell lines was
comparable to that of the pLKO.1 control cell line
(Figure 3B). In contrast, comparable cIV in-gel activity
was observed in control and all NDUFB11-depleted cell
lines (Figure 3B). Accordingly, the cI enzymatic activity
was extremely low in the shRNA-1 cells with respect to
the pLKO.1 control cells, but the other complex activities
were comparable to the control values (Table S4). These re-
sults demonstrate a direct relationship between the
decreased NDUFB11 amount and the catalytic activity of
the cI holocomplex.
To further investigate how the knockdown of NDUFB11
affects cI assembly, we performed second-dimensional
(2D) BNGE on shRNA-1 and pLKO.1 cell lines (Figure 3C).
Immunoblot analysis was carried out with antibodies
that probed three topologically distinct cI subunits
(a-NDUFB11, a-NDUFA9, and a-NDUFS3). a-NDUFB11 re-
vealed a barely detectable signal in shRNA-1 cells (right
panel in Figure 3C), whereas pLKO.1 control cells dis-
played a strong reactive band corresponding to the fully
assembled cI and to different membrane-arm subcom-
plexes (left panel in Figure 3C). NDUFA9 is a cI subunit
that is incorporated late during assembly and is located
at the joint connecting the membrane and the peripheral
arms.49 The NDUFA9-specific signal was weak and non-
focalized in shRNA-1 cells (right panel in Figure 3C),erican Journal of Human Genetics 96, 640–650, April 2, 2015 645
Figure 4. NDUFB11 Is Necessary for Respiratory Activity
The oxygen consumption rate was measured in NDUFB11-knock-
down (shRNA-1 and -2) and control (pLKO.1) cells with the high-
resolution oxygraph OROBOROS (Oroboros Instrument) as
described previously.53 Cellular respiration was measured in basal
conditions (endogenous) in the presence of oligomycin (leaking)
and in the presence of FCCP (uncoupled). For calculation of the
respiratory rates, the oxygen consumption per minute was
normalized to the cell number. Statistical significance was deter-
mined by ANOVA and is indicated as follows: *p<0.05; **p <
0.01; ****p < 0.0001; n ¼ 3. The plotted values correspond to
the mean5 SD.whereas it was readily detected in pLKO.1 control cells
(left panel in Figure 3C). NDUFS3 is incorporated early
in the assembly pathway into sub-assembled species that
eventually form the peripheral arm.50 Although the
amount of NDUFS3-specific signal was comparable in
both shRNA-1 and pLKO.1 control cells (Figure 3A), 2D-
BNGE immunoblotting clearly showed the presence of
several aberrant sub-assembly intermediates containing
NDUFS3 in the shRNA-1 cells but hardly any cI holocom-
plex. On the contrary, most of a-NDUFS3 was present in
the cI holocomplex in pLKO.1 control cells (left panel in
Figure 3C). Normal assembly of the cIV complex was
demonstrated in both shRNA-1 and pLKO.1 control cells
(Figure 3C).
Finally, we tested whether defective cI assembly and ac-
tivity upon NDUFB11 knockdown could impair mito-
chondrial respiration. Endogenous, leak (or state 4), and
uncoupled (maximal rate) respiration were sequentially
determined with high-resolution respirometry (Oro-
boros). That is, by measuring oxygen consumption
without any external additions; in the presence of oligo-
mycin, an inhibitor of the mitochondrial ATP-synthase
(cV); and finally in the presence of the OXPHOS-uncou-
pler FCCP (carbonyl cyanide-p-trifluoromethoxyphenyl-
hydrazone)..51,52 Compared to respiration-rate values in
pLKO.1 control cells, respiration-rate values were reduced
4-fold in shRNA-1 NDUFB11-depleted cells (Figure 4). In
HeLa cells expressing shRNA-2, oxygen consumption
was also decreased, but not as profoundly as in shRNA-1
cells (Figure 4). This is in accordance with the drastically
reduced amount of NDUFB11 in shRNA-1 compared to
shRNA-2 knockdown HeLa cells (Figure 3A). Together,
these data demonstrate that the NDUFB11 subunit is646 The American Journal of Human Genetics 96, 640–650, April 2, 2indispensable for assembly of the cI membrane arm, for
maturation of the cI holocomplex, and for cI-dependent
mitochondrial respiration.
Our data clearly demonstrate the importance of
NDUFB11 for cI biogenesis and mitochondrial respiration,
suggesting that severe cI deficiency underlies the develop-
mental defects in MLS-affected individuals with the
NDUFB11mutation. A combined effect of OXPHOS defects
and enhanced cell death has been shown to underlie the
brain and eye abnormalities observed in a hccs-deficient
medaka fish model.18 In order to investigate whether
NDUFB11-knockdown cells have a proliferative disadvan-
tage in comparison to control cells, we monitored cell
growth of the shRNA-transduced versus control HeLa cells
and demonstrated that cells in which the knockdown of
NDUFB11 was most severe (shRNA-1) showed significantly
reduced growth (Figure S2). To determine whether the
reduced growth of NDUFB11 knockdown cells correlates
with increased apoptosis in these cells, we quantified an
early marker of apoptosis (i.e., externalization of phospha-
tidylserine in the cell membrane) by using the specific
apoptosis marker Annexin V (FITC conjugated to Annexin
V). As compared to that of pLKO.1 cells, the proportion of
shRNA-1 NDUFB11-depleted cells positive for Annexin V
was significantly increased (Figure 5). In conclusion, a
reduced amount of NDUFB11 is associated with slower
cell growth and increased apoptosis, suggesting that cells
expressing the NDUFB11 mutant allele are likely to be
offset by those expressing the normal allele and eventually
to be selected out.
Our results show that X-linked gene mutations leading
to severe MRC impairment, including severe cI deficiency,
in addition to already documented defects of cIII and cIV,
underlie MLS syndrome. cI is the biggest MRC enzyme
and a major entry point of respiration. cI strips two elec-
trons from NADH and transfers them to ubiquinone by
using the redox potential to pump four protons across
the inner mitochondrial membrane and thus contrib-
uting to the maintenance of the electrochemical
gradient.43 cI deficiency is the most common respira-
tory-chain defect in human mitochondrial disorders. To
date, mutations in genes coding for all 14 core subunits,
including seven mtDNA-encoded subunits, have been re-
ported to cause isolated cI deficiency. In addition, muta-
tions in 11 genes encoding supernumerary subunits,
including mutations reported here in NDUFB11, have
been found in individuals with cI deficiency, indicating
that these genes play an essential role in cI assembly
and/or stability.45,54 The phenotypic spectrum associated
with cI deficiency ranges broadly, from fatal neonatal
lactic acidosis and infantile-onset Leigh syndrome to
childhood-onset mitochondrial encephalopathy, lactic
acidosis, and stroke-like episodes (MELAS) syndrome. Sin-
gle organ involvement has also been reported; examples
include isolated hypertrophic cardiomyopathy, isolated
skeletal myopathy, and Leber’s hereditary optic neuropa-
thy (LHON).45 Remarkably, early-onset cardiomyopathy015
Figure 5. NDUFB11-Depleted HeLa Cells
Show Enhanced Apoptosis
(A) The data were generated by the Nu-
cleoCounter NC-3000 system (Chemo-
Metec). This assay uses Hoechst 33342
to stain DNA and detect the total
amount of cells. Staining cells with a
conjugate of Annexin V and FITC al-
lowed detection of cells in which phos-
phatidylserine is flipped inside out and
exposed to the outer layer of the plasma
membrane, a phenomenon occurring in
the early execution phase of apoptosis.
Cells were also stained with propidium
iodide (PI) so that the non-viable (i.e.,
necrotic and late apoptotic) ones could
be detected. The scatter plots show the
intensity of Annexin-V-FITC versus PI
fluorescence. Low Annexin-V-FITC/low
PI intensity (lower left quadrant) corre-
sponds to normal cells; high Annexin-
V-FITC/low PI intensity (lower right
quadrant) corresponds to cells in early
apoptosis.
(B) Quantification plot of the per-
centage of healthy and early apoptotic
cells in control (pLKO.1) and NDUFB11
knockdown (shRNA-1) cells. Statistical significance was determined by ANOVA and is indicated as follows: **p < 0.01;
***p < 0.001; n ¼ 3. The plotted values correspond to the mean 5 SD.was present in subjects 1 and 2 as well as in the aborted
female fetus from family 2. After autopsy, histiocytoid car-
diomyopathy was diagnosed in subject 1. Hypertrophic
and oncocytic (histiocytoid) cardiomyopathy has been re-
ported in a few individuals with MLS syndrome.8,9,55 In
particular, in one deceased girl with an HCCS nonsense
mutation, histiocytoid cardiomyopathy was found after
a post-mortem examination.2 Interestingly, dilated or hy-
pertrophic cardiomyopathy was observed in a proportion
of female mice with heart-specific inactivation of one
Hccs copy.29 Our results, combined with the marked
expression of Ndufb11 observed in the mouse heart (Bio-
GPS database),56 suggest that NDUFB11 is an attractive
candidate for involvement in isolated histiocytoid cardio-
myopathy.57
HCCS, COX7B, and NDUFB11, which are involved in
cellular respiration, are ubiquitously expressed (BioGPS
database),56 but developmental defects in MLS-affected
individuals are mainly restricted to the skin, eyes, and
CNS (Table 1). Given that skin involvement is uncommon
in canonical mitochondrial disorders, these findings
imply the existence of a new pathogenetic mechanism
affecting skin development in severe, X-linked forms of
OXPHOS failure. Our data suggest that severe cI defi-
ciency in specific cell types of females with a heterozygous
NDUFB11 mutation might cause increased cell death and
underlie the developmental defects in individuals with
MLS syndrome. A proliferative advantage of cells with
an active wild-type X chromosome might compensate
for the loss of NDUFB11-deficient cells, as demonstrated
in mice with heart-specific Hccs inactivation.29 In support
of this idea, we showed that NDUFB11 knockdown alsoThe Amcaused slower cell growth and increased apoptosis,
although the knockdown experiments in cell culture
cannot perfectly recapitulate functional mosaicism in
female subjects as a result of random X-chromosome inac-
tivation. The regenerative capacity and compensatory
proliferation of healthy cells during embryonic develop-
ment might lead to the most favorable outcome (i.e., no
apparent sign of MLS syndrome). This possibility is sup-
ported by incomplete penetrance in oligo-symptomatic
individuals as well as in apparently healthy female car-
riers,2 including the NDUFB11-mutation-positive mother
of subject 2.
In summary, MLS syndrome is a developmental disorder
caused by the complex interplay between X inactivation
and OXPHOS defects of cIII, cIV, or, as shown here, cI.
Because of the primary OXPHOS failure, it is possible
that marked ATP depletion, abnormal reactive oxygen spe-
cies (ROS) generation, and increased cell death are interre-
latedmechanisms contributing to the pathogenesis ofMLS
syndrome. Indeed, MRC impairment and increased pro-
duction of ROS have been shown to trigger an increase
in caspase-dependent apoptosis in the eyes and brains of
hccs-deficient medaka embryos, suggesting that the devel-
opmental defects seen in individuals with MLS syndrome
are caused by a combined effect of OXPHOS defects and
enhanced cell death, possibly through the synergic contri-
bution of decreased ATP and increased ROS production.18
Although more work is warranted to test these hypotheses
mechanistically in in vivo models of NDUFB11 deficiency,
our results in shRNA-1 HeLa cells do suggest that apoptosis
plays a relevant pathogenetic role in NDUFB11-associated
MLS syndrome.erican Journal of Human Genetics 96, 640–650, April 2, 2015 647
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